# Arkis BioSciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arkis-biosciences

- Industry: Medical Devices & Equipment
- Headquarters: Knoxville, US
- Website: www.arkisbiosciences.com
- Total disclosed funding: $6.4M
- Latest round: Series A (Jan 12, 2018)
- Investors on record: 3

## About

Arkis BioSciences Inc. is a biotechnology company focused on developing innovative medical devices for various neurosurgical applications, enhancing patient outcomes through advanced technology solutions.Founded in 2011 and headquartered in Knoxville, US, Arkis BioSciences Inc. specializes in the advancement of medical devices for neurosurgery. In August 2018, the company raised USD 4.48 mn in venture funding from unspecified investors, having completed a total of 7 deals since inception.Arkis BioSciences Inc. specializes in advanced medical devices aimed at neurosurgical applications. Their flagship product, the CerebroFlo® EVD Catheter, is designed for temporary insertion into the brain's ventricular cavity to assist in the external drainage of cerebrospinal fluid (CSF) for patients suffering from elevated intracranial pressure, intraventricular hemorrhage, or hydrocephalic shunt infections. The catheter incorporates Endexo® Technology, which significantly reduces fibrinogen and platelet activation, thus decreasing thrombus formation and potentially improving patient outcomes. The company's products primarily serve healthcare providers and physicians in neurosurgery across hospitals and surgical centers in the United States, Europe, and Asia.Arkis BioSciences Inc. generates revenue predominantly through the direct sale of its medical devices, including the CerebroFlo® EVD Catheter. The company engages in B2B transactions with healthcare facilities that utilize these specialized products for critical neurosurgical procedures. Sales typically consist of one-time purchases or ongoing supply contracts based on patient needs and surgical schedules, although specific pricing details remain proprietary.Following the most recent funding round in August 2018, which raised USD 4.48 mn, Arkis BioSciences Inc. plans to utilize these funds to enhance product development and explore new market opportunities. The company is focused on designing new neurosurgical devices and aims to expand its presence in the European and Asian markets by 2022, aligning with their strategic goals for broader geographic reach.

## Funding rounds

- Series A, Jan 12, 2018, $3M — Innova Memphis
- Series A, Jun 24, 2016, $3.4M — Lighthouse Funds, Sheltowee Angel Network, Innova Memphis

## Investors

- Lighthouse Funds (https://capitalatlas.ai/funds/lighthouse-funds) — Series A
- Sheltowee Angel Network (https://capitalatlas.ai/funds/sheltowee-angel-network) — Series A
- Innova Memphis (https://capitalatlas.ai/funds/innova-memphis) — Series A